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Recent studies have suggested that aneuploidy in malignant tumours could be a consequence of centrosome aberrations. Using
immunofluorescence analysis with an antibody against g-tubulin and DNA image cytometry, we measured centrosome aberrations
and DNA ploidy patterns in fine-needle aspiration biopsies (FNABs) of 58 breast lesions. Benign lesions did not show any
centrosome aberrations. DNA diploid carcinomas showed a mean percentage of cells with centrosomal defects of 2.1%. The
aneuploid invasive carcinomas could be divided into two subgroups by their significantly (P¼0.0003) different percentage of cells
with centrosome aberrations (2.0 and 10.3%, respectively) and their significantly (P¼0.0003) different percentage of cells with
nonmodal DNA content values determined by the Stemline Scatter Index (SSI), a measure of genomic instability. The percentage of
cells with centrosome aberrations demonstrated a positive, linear correlation with the corresponding SSI (r¼0.82, Po0.0001) and
loss of tissue differentiation (r¼0.78, Po0.0001). Our results indicate the percentage of cells with centrosome aberrations as being
sufficient to divide the investigated tumours into three significantly different groups: benign lesions with no centrosomal aberrations,
and two malignant tumour types with mean values of 2.1 and 9.6% of centrosomal defects, respectively. Together, these results
demonstrate that centrosome aberrations correlate with genomic instability and loss of tissue differentiation. Furthermore, this study
shows the feasibility of centrosomal analysis in FNAB of the breast and suggests centrosomal aberrations as possessing diagnostic and
prognostic value.
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Fine-needle aspiration biopsy (FNAB) is a well established, low
cost, rapid and minimally invasive technique for diagnosing
suspicious breast lesions that can reduce the need of surgical
biopsies by preoperative diagnosis (Franzen and Zajicek, 1968;
Arisio et al, 1998). The accuracy through which lesions can be
targeted has been improved by sonography and mammography
guided aspiration techniques. However, diagnosis in cytological
specimens is in general more difficult than in histological ones,
because information about epithelial cell growth pattern and
connection with the surrounding tissue are lost. Consequently,
diagnosing cytological samples, in particular from early and highly
differentiated carcinomas, remains challenging not only due to the
absence of histomorphological structures but also because of the
frequently minute cytomorphological alterations. Hence, the
requirement of additional and objective information is of utmost
priority. Centrosome aberrations seem to be characteristic of
malignant tumours in general (Pihan et al, 1998). Normally, the
centrosome as the major microtubule organisation centre in
mammalian cells regulates the number, stability, polarity and
arrangement of microtubules in interphase cells (Rose et al, 1993;
Kellogg et al, 1994). In this context, the centrosome and
microtubules play an important role in maintaining overall cell
polarity and provide an architectural framework for several cell
functions. Once in each cell cycle the centrosome duplicates itself
(Stearns, 2001). During G2–M phase transition, replicated
centrosomes separate to guarantee correct chromosome segrega-
tion by formation of a bipolar mitotic spindle (Kellogg et al, 1994;
Meraldi et al, 1999). Under normal conditions, the centrosome
duplication cycle proceeds in exact coordination with the DNA
replication (Sluder and Hinchcliffe, 2000; Hinchcliffe and Sluder,
2001). Failure of coordination of centrosome duplication and DNA
replication may lead to centrosome aberrations, possibly followed
by segregation errors of chromosomes at cell division, and thus to
aneuploidy and genomic instability (Brinkley and Goepfert, 1998;
Orr-Weaver and Weinberg, 1998; Ghadimi et al, 2000).
In this study we focused on primary breast carcinomas, which
are classically divided into two major groups, that is, DNA diploid
and DNA aneuploid tumours by means of DNA content-based
histogram analysis. A number of prospective and retrospective
studies revealed DNA aneuploid breast carcinomas as following a
more malignant course than DNA diploid breast carcinomas do
(Auer et al, 1980, 1984; Fallenius et al, 1988b). Recently, we have
shown that aneuploid breast cancers can be subdivided into a
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sgenomically stable and unstable group by their proportion of cells
with nonmodal DNA content values in the respective cytometrical
DNA histograms, where the stable group proved to have a more
favourable prognosis (Kronenwett et al, 2004). Here we show the
feasibility of centrosome analysis in fine-needle aspirates of breast
lesions. We explore the relationship between centrosome defects
(aberrant centrosome number and size), DNA ploidy and genomic
instability.
MATERIALS AND METHODS
Patient samples
In total, 51 consecutive FNABs of breast lesions, including 33
invasive carcinomas and 18 benign lesions, were collected at Cell
and Molecular Analysis, Karolinska Hospital, during 2000–2001.
Furthermore, seven FNABs of ductal carcinomas in situ (DCIS)
were included in our analysis to characterise preinvasive lesions.
The invasive carcinomas comprised 31 ductal carcinomas (DC),
one lobular carcinoma (LC) and one medullar carcinoma (MC).
The benign lesions consisted of 10 mastopathias and eight
fibroadenomas. None of the patients received any type of
therapeutic treatment before FNAB. The aspirates were subjected
to cytopathological assessment, centrosomal analysis and image
cytometric DNA content measurement. All cytologically diagnosed
malignancies and all suspicious lesions were operated and
examined histopathologically (Table 1).
FNAB
FNAB was performed using a 23-gauge needle attached to a 10ml
syringe and inserted into a syringe holder as described earlier
(Franzen and Zajicek, 1968; Auer et al, 1980). All aspirations were
performed by the same experienced pathologist (GA). Cells from
nonpalpable lesions were aspirated under guidance of ultrasound
or mammography (Fornage et al, 1992). The aspirates were
smeared on microscope slides for cytopathological evaluation after
May–Gruenwald–Giemsa staining.
DNA image cytometry
Image cytometry was performed on Feulgen stained FNABs to
measure the nuclear DNA content. The staining, the internal
standardisation and the tumour cell selection were based on
previously described methods (Auer et al, 1980). All DNA
values were calculated in relation to a corresponding staining
control, which obtained the value 2c, denoting the diploid
DNA content. On average, we measured 350 morphologically
selected cells per aspirate. The cell population of each specimen
was characterised according to two principles, based upon
nuclear DNA content measurements. First, we divided the tumours
into the already known groups: type I, with a diploid stemline
(1.8c–2.2c), o5% of the cells in S phase and no cells exceeding 5c;
type II, with a tetraploid stemline (3.8c–4.2c) and o5% of the cells
exceeding 5c; type III or diploid proliferative, with a diploid
stemline, but X5% of the cells being in S phase; and type IV or
aneuploid, with one peak or more outside the diploid or tetraploid
region (Auer et al, 1980, 1989). Furthermore, we applied the
Stemline Scatter Index (SSI) to the 58 breast lesions, a measure of
the percentage of tumour cells with nonmodal DNA content values,
or of the degree of scattering of DNA histograms (Kronenwett et al,
2004). The SSI is the sum of the percentage of cells with DNA
content values in the S-phase region (S phase), plus the percentage
of cells with DNA content values exceeding twice the modal value
plus 1c (G2 exceeding rate, or G2 Exc), plus the coefficient of
variation (CV) of the respective tumour stemline (SSI¼S
phaseþG2 ExcþTum CV). We used the cut point value of
SSI¼8.8% (Kronenwett et al, 2004) to differentiate between all
lesions showing significantly scattered DNA histograms
(SSI48.8%) and those with insignificantly scattered ones
(SSIp8.8%). Breast lesions with an SSI p8.8% were termed
genomically stable (gs), and those with an SSI48.8% were termed
genomically unstable (gu).
Centrosome staining
The FNABs were smeared on a glass slide and shortly air-dried.
Then the aspirated cells were fixed in methanol at  201C for
10min and in acetone at  201C for 6min. Blocking solution (1%
normal goat serum (NGS) and 0.1% Tween 20 in PBS) was applied
to the cells for 30min at 371C. Cells were incubated with an anti-g-
tubulin monoclonal antibody (Sigma-Aldrich, St Louis; diluted
1:1000 in PBS, containing 2% NGS) for 1h. Antibody–antigen
complexes were detected by Cy3-conjugated anti-mouse IgG
(Jackson Immuno Research, West Grove; 1:200, 2% NGS/PBS
for 1h at room temperature). After each incubation, cells were
extensively rinsed with PBS. Then DNA was visualised by staining
with DAPI (40,6-diamino 2-phenylindole, Sigma-Aldrich) for 5min
at room temperature. After washing in PBS for 5min, the stained
slides were mounted with mounting medium (Vectashield, Vector
Laboratories, Peterborough, UK) and covered with a cover slide.
The immunofluorescence staining was evaluated using a fluores-
cence microscope (Leica DM RXA), and the centrosome images
were obtained with the aid of Leica Q-FISH software. The
percentage of cells with centrosome aberrations was determined
by dividing the number of cells showing more than two
centrosomes (¼g-tubulin-stained spots), or centrosomes with
apparently aberrant morphology (a diameter of greater than twice
the diameter of centrosomes of nontumour control cells) by the
number of investigated cells. At least 500 cells per aspirate were
examined. All slides were coded and evaluated by two investigators
independently.
Statistical analysis
The significance of correlation of centrosome aberrations with SSI
and centrosome aberrations with Elston grade were assessed
according to Spearman. For group discrimination significance
Table 1 Patient age and breast cancer characteristics
Age (years) 59 (28–87)
Histological type
Ductal 31 (53.5%)
Lobular 1 (1.7%)
Medullar 1 (1.7%)
DCIS
a 7 (12.1%)
Mastopathia 10 (17.2%)
Fibroadenoma 8 (13.8%)
Tumour size (carcinomas and DCIS)
b
T1b 7 (17.5%)
T1c 26 (65.0%)
T2 6 (15.0%)
Not determined 1 (2.5%)
Grade (invasive carcinomas)
c
Elston Grade 1 6 (18.2%)
Elston Grade 2 17 (51.5%)
Elston Grade 3 10 (30.3%)
aClassification according to Ottesen et al (1992).
bTumour-Node-Metastasis
classification (Union International Contre Cancer) 1997.
cElston–Ellis modification
of Scarff–Bloom–Richardson grading system (CW Elston and JO Ellis).
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were calculated with the aid of SPSS.
RESULTS
In this study 31 DC, one LC, one MC, seven DCIS, 10 mastopathias
and eight fibroadenomas were characterised by their centrosomal
status and their cytometrical DNA content histogram. All samples
were obtained by FNAB.
DNA image analysis
In total, 65% (20 out of 31) of the DC, the one (one out of one) MC
and all (seven out of seven) DCIS were aneuploid (A), whereas 35%
(11 out of 31) of the DC, the one (one out of one) LC and all (18 out
of 18) benign lesions were diploid (D). Despite the fact that all
DCIS in this study were A, a previous study from our group
showed 63% of DCIS as being A and 37% as being D (Pallis et al,
1992).
By using the cut point value of SSI¼8.8%, we determined seven
Ags tumours (gs: SSI p8.8%, Figure 1B) and 14 Agu specimens
(gu: SSI48.8%, Figure 1D) among the invasive A carcinomas. The
seven DCIS were found to be Agu as well. The invasive D
carcinomas (n¼12, Figure 1C) and benign D lesions (n¼18,
Figure 1A) were all gs.
Centrosomal status
The tumour aspirates were immunostained with an antibody
against g-tubulin, a well-characterised marker of the centrosome
(Stearns et al, 1991; Joshi et al, 1992; Schiebel, 2000). Centrosome
aberrations were investigated by the determination of the
percentage of cells with more than two centrosomes (g-tubulin-
stained spots) and centrosomes with apparently aberrant mor-
phology: a diameter of greater than twice the diameter of
centrosomes of normal breast cells and fibroblasts in imprints.
The investigated aspirates differed distinctly concerning the extent
of centrosome defects. None of the benign lesions (10 masto-
pathias and eight fibroadenomas) had any centrosome aberrations
(0%, Figure 2A). The Ags carcinomas (n¼7) showed a mean
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Figure 1 Diploid and aneuploid DNA histograms of fine-needle aspiration biopsies of the breast. Nuclear DNA content of the cells on the horizontal axis
is normalised to the nuclear DNA content of leukocytes (2c denotes diploid DNA content). (A) DNA profile of a fibroadenoma, (B) profile of a
genomically stable (gs) aneuploid carcinoma, (C) DNA histogram of a gs diploid carcinoma, and (D) profile of a genomically unstable aneuploid carcinoma.
Figure 2 Centrosome staining of fine-needle aspiration biopsies of
genomically stable (gs) breast lesions. Centrosomes are immunostained
with a monoclonal antibody against g-tubulin. The fibroadenoma (A) shows
no centrosome aberrations, that is, two centrosomes (red) per nucleus
(blue). gs diploid (B, C) and gs aneuploid (D) carcinomas show a low range
of supernumerary centrosomes and occasionally centrosomes with larger
size (B).
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(s.d.¼0.26, Figure 2D), similar to that in Dgs carcinomas
(n¼12) with a mean percentage of 2.1% (s.d.¼0.26, Figure 2B
and C). The invasive Agu breast carcinomas (n¼14) had the
highest percentage of cells with centrosomal aberrations with a
mean value of 10.3% (s.d.¼1.66, Figure 3A–C). The correspond-
ing value in the Agu DCIS specimens (n¼7) was 8.2%
(s.d.¼1.35). Most frequently observed abnormalities were cells
with supernumerary centrosomes (range: 3–11).
The investigated specimens could be divided into three
significantly different groups, regarding their centrosomal status:
(1) benign lesions with no measurable centrosomal aberrations; (2)
malignant tumours with a low extent of cells with centrosomal
aberrations, including Dgs and Ags carcinomas with a mean value
of centrosome aberrations of 2.1% (s.d.¼0.26); and (3) malignant
tumours with a higher extent of cells with centrosomal defects,
including invasive Agu and Agu DCIS with a mean value of 9.6%
(s.d.¼1.82) (Figure 4, Table 2). Furthermore, the invasive A
carcinomas could be divided into two subgroups (Agu and Ags) by
their significantly different percentage of cells with centrosome
aberrations and their significantly different fraction of cells with
nonmodal DNA content values measured by the SSI (Table 2). The
significance of differences between the aforementioned groups is
indicated in Table 3. Our results also permit division of the FNAB
specimens into the same three groups from above, using the SSI as
separation criterion (Tables 2 and 3). However, to separate benign
from malignant breast tumours, we need to investigate a larger
number of benign lesions, in order to determine a cut point of SSI
between these two groups and to be able to validate the cut point.
We found a significant, linear correlation between SSI and
percentage of cells with centrosome aberrations (r¼0.82,
Po0.0001). Also, the percentage of cells with centrosomal
anomalies did correlate with increased Elston grade in the invasive
carcinomas (r¼0.78, Po0.0001), suggesting a relationship be-
tween centrosomal aberrations and cytological events, leading to
loss of tissue differentiation.
DISCUSSION
In this study, we characterised 58 FNABs of breast lesions by their
centrosomal status and DNA content-based histogram. We found
that centrosome aberrations correlate with genomic instability, as
indicated by a high percentage of cells with nonmodal DNA
content values, measured by the SSI, and loss of tissue
differentiation. Already preinvasive lesions showed centrosomal
aberrations, suggesting centrosome abnormalities as being an early
step in breast carcinogenesis. The investigated breast lesions could
be divided into benign lesions (no centrosomal aberrations) and
two subgroups of malignant tumours, by their significantly
different extent of cells with centrosomal aberrations.
Image cytometry measurements are carried out to identify
aneuploidy, which is the most frequent manifestation of genomic
instability in human malignancies (Mertens et al, 1997; Sen, 2000).
Type IV histograms, those of aneuploid tumours (Auer et al, 1980),
are suggested to indicate populations of interphase nuclei with
decreased genomic stability (Auer et al, 1989). Although DNA
ploidy measurement does not reveal information about the
distribution of genomic imbalances, several studies using this
method have supported the conclusion that DNA aneuploidy is
closely associated with poor prognosis in various cancers (Ross,
1996; Magennis, 1997). In breast cancer the prognostic significance
of DNA content has been shown in several studies (Auer et al,
1984; Fallenius et al, 1988a,b; Siitonen et al, 1993). Using Cox
multivariate analysis, nuclear DNA content was found to provide
significant prognostic information, independent of any other
clinical and histomorphological variables (Fallenius et al, 1988a).
Figure 3 Centrosome staining of fine-needle aspiration biopsies of
genomically unstable (gu) aneuploid breast carcinomas. Centrosomes are
immunostained with a monoclonal antibody against g-tubulin. gu aneuploid
carcinomas (A–C) demonstrate a high range of supernumerary centro-
somes (red spots). Centrosomes are more often of larger size (B, C) than
in genomically stable tumours.
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content histograms. Applying the SSI value (Kronenwett et al,
2004), we were able to further subdivide aneuploid breast lesions
into gs and gu types. We found that scattering of DNA profiles as a
measure of genomic instability correlates highly significantly with
centrosome aberrations. While centrosome abnormalities have
been reported earlier in different human malignancies (Pihan et al,
1998; Ghadimi et al, 2000; Skyldberg et al, 2001; Roshani et al,
2002), including breast cancer (Lingle et al, 1998; Lingle and
Salisbury, 1999), a difference in the extent of centrosome
aberrations in cytometrically determined subtypes of breast
carcinomas has, to our knowledge, not been reported by other
authors.
None of the benign breast lesions showed any centrosomal
defects. In contrast, all carcinomas exhibited centrosomal aberra-
tions. Interestingly, invasive gs diploid and gs aneuploid
carcinomas demonstrated a comparable percentage of cells with
centrosomal abnormalities (mean value 2.1%), which differed
distinctly from the approximately five times higher value, observed
in the invasive gu aneuploid tumours (mean value 10.3%). These
results confirm our data received from a former study, where we
investigated three gs aneuploid and diploid breast carcinomas
each, and four gu aneuploid ones (Kronenwett et al, 2004).
In accordance with findings from other authors (Lingle et al,
2002; Pihan et al, 2003), we detected centrosome aberrations
already in noninvasive breast lesions (DCIS), suggesting centro-
some aberrations as being an early event in the complex process of
breast carcinogenesis. The range of centrosome aberrations in the
DCIS was very similar (even though slightly lower) to that of their
invasive counterparts and consistent with their ploidy pattern.
Using fluorescence in situ hybridisation with probes for chromo-
somes 3, 7 and 17,Lingle et al (2002) could distinguish between
stable and unstable aneuploid breast carcinomas. The stable
specimens possessed only few defects in centrosome number and
size, which in turn correlated with chromosomal stability. These
findings are in accordance with our results. The gs breast
carcinomas characterised by us still seem to have a quite well-
regulated cell cycle as shown in cyclins A and E mRNA expression
studies, and they possess only a low percentage (p8.8%) of cells
with nonmodal DNA content values, indicating a homogeneous
tumour cell population. Furthermore, they prove to have a better
prognosis than the gu breast carcinomas (Kronenwett et al, 2004).
Centrosome aberrations in gs aneuploid specimens are in the
range of those found in gs diploid ones.
Comparative genomic hybridisation analysis of DNA diploid
breast carcinomas revealed few copy number changes that involve
mainly the gain or loss of entire chromosomes or chromosomal
arms (Ried et al, 1995), an observation that may indicate a
segregation error as a primary event in carcinogenesis. Such
segregation errors could be the consequence of supernumerary
centrosomes. An electron microscopy study (Lingle and Salisbury,
1999) revealed that multiple centrosomes in breast cancer cells
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Figure 4 Three significantly different groups of breast lesions regarding
the centrosomal status: (1) benign (’) no centrosomal aberrations; (2)
malignant with a low extent of cells with centrosomal aberrations:
genomically stable (gs) diploid (J) and gs aneuploid (m); (3) malignant
with a higher extent of cells with centrosomal aberrations: invasive
genomically unstable (gu) aneuploid and gu aneuploid in situ (~). There is a
positive linear correlation between SSI (Stemline Scatter Index) and the
percentage of cells with centrosome aberrations (r¼0.82, Po0.0001).m
Table 2 Centrosome aberrations and stemline scatter index (SSI)
Percentage of cells with centrosome aberrations SSI (%)
n Mean (95% confidence interval) Median s.d. Mean (95% confidence interval) Median s.d.
All 58 4.14 (3.00–5.29) 2.10 4.35 12.68 (9.02–16.33) 6.50 13.90
(a) Benign lesions 18 0 0 0 4.88 (4.23–5.53) 4.70 1.31
(b) D
ags
b+A
cgs 19 2.06 (1.93–2.18) 2.00 0.26 5.90 (5.25–6.55) 6.20 1.37
Dgs 12 2.12 (1.95–2.28) 2.10 0.26 5.65 (4.91–6.39) 6.15 1.17
Ags 7 1.96 (1.71–2.20) 1.90 0.26 6.33 (4.82–7.84) 7.40 1.64
(c) Agu
d invasive+Agu DCIS
e 21 9.58 (8.75–10.41) 9.30 1.82 25.49 (17.93–33.06) 19.40 16.62
Agu invasive 14 10.26 (9.30–11.22) 10.25 1.66 28.59 (17.72–39.46) 20.45 18.83
Agu DCIS 7 8.21 (6.97–9.46) 8.10 1.35 19.30 (10.74–27.86) 17.80 9.25
aType I carcinomas with a diploid (D) stemline.
bGenomically stable (gs) tumours.
cType IV carcinomas with an aneuploid (A) stemline.
dGenomically unstable (gu) tumours.
eDuctal Carcinoma In Situ (DCIS).
Table 3 Mann–Whitney U-test of significance of group differences
Tested groups
Centrosome
aberrations
Stemline Scatter
Index (SSI)
a
a–b
b Po0.0001 P¼0.0308
a–c
c Po0.0001 Po0.0001
b–c Po0.0001 Po0.0001
c–A
dgs
e Po0.0001 Po0.0001
Agu
f invasive – Ags P¼0.0003 P¼0.0003
Agu invasive – D
ggs Po0.0001 Po0.0001
aBenign lesions.
bGenomically stable (gs) type I carcinomas with a diploid (D) stemline
and gs type IV carcinomas with an aneuploid (A) stemline.
cGenomically unstable (gu)
invasive A carcinomas and Agu carcinomas in situ.
dType IV carcinomas with an
aneuploid (A) stemline.
eGenomically stable (gs) tumours.
fGenomically unstable (gu)
tumours.
gType I carcinomas with a diploid (D) stemline.
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scould lead to multipolar mitosis or via coalescence of two or more
centrosomes to bipolar spindles. Thus, the existence of multiple
centrosomes might promote genomic instability by increasing the
probability of chromosomal segregation errors to occur, whereas
through coalescence of excess centrosomes a proportion of bipolar
mitosis for tumour growth is maintained. Consequently, centro-
some aberrations might play an important role in carcinogenesis
and in malignant tumours promote further karyotypic hetero-
geneity. This is supported by our findings, showing that
centrosome aberrations are already present in in situ lesions, that
is, before invasiveness. Additionally, centrosomal aberrations
correlate with genomic instability (as mirrored in the degree of
scattering of DNA histograms measured by the SSI) and with loss
of tissue differentiation.
All patient samples used for centrosomal and DNA content
analysis were obtained with the aid of FNAB. While DNA ploidy
measurements are frequently performed on aspirates, to our
knowledge this is the first report, which demonstrates the
feasibility of centrosomal analysis in FNAB of the breast.
Benign breast diseases, such as mastopathia and fibroadenoma,
did not reveal any centrosomal aberrations. Thus, with only one
single marker – the percentage of cells with centrosome
aberrations – benign lesions were readily discernable from
carcinomas/DCIS. Centrosome aberrations revealed in this context
more information than did DNA ploidy measurements, because
ploidy measurements cannot discriminate benign and malignant
diploid lesions. In addition, determining the extent of cells with
centrosomal aberrations enabled us to divide the breast cancers
into two significantly different subgroups, namely genomically
stable and unstable carcinomas.
In a former study, high SSI values were related to unfavourable
prognosis (Kronenwett et al, 2004). The percentage of cells with
centrosome aberrations shows a positive linear correlation with
the SSI and, therefore, might be of prognostic value. Further
investigations in a larger collective of patients and a sufficient
follow-up period are needed to prove the diagnostic and
prognostic value of centrosome aberrations in FNABs of the breast.
In summary, our results demonstrate centrosome aberrations as
correlating with genomic instability manifested in a high
percentage of nonmodal DNA content values, and loss of tissue
differentiation. Our results further indicate that centrosome
abnormalities might be an early event in the development of
breast cancer. The study confirms our previous data (Kronenwett
et al, 2004), where gs and gu aneuploid breast lesions differed
significantly from each other, and gs diploid and gs aneuploid
specimens did not. While this has been mainly demonstrated by
DNA histogram analysis and cyclin A and E expression studies
before, we show here the two aneuploid subgroups as differing
significantly in their centrosomal status as well. Thus, with only
one parameter – the percentage of cells with centrosomal
aberrations – we could clearly discriminate benign from malignant
breast lesions; and in the malignant group, we were able to
distinguish two significantly different subgroups. Our results
indicate that the characterisation of FNABs of the breast by
centrosomal analysis and image cytometry, as a low cost but highly
informative method, might support diagnosis and prognosis of
breast tumours.
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